Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicentre, Phase 3 Study to Demonstrate the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event During 24 Months Followup

NCT00785044 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT00785044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00785044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicentre, Phase 3 Study to Demonstrate the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event During 24 Months Followup
Lead sponsor
GE Healthcare
Phase
Observational
Overall status
Completed
Start date
May 31, 2008
Completion date
February 28, 2010
Enrollment
471 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

congestive heart failure